Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 116 publications
Nilotinib in chronic myeloid leukemia: clinical value, real-world challenges, and the potential of nilotinib tablets to improve therapeutic outcomes.
Journal: Expert review of hematology
Published: August 12, 2026
Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular Therapy.
Journal: Transplantation and cellular therapy
Published: August 10, 2026
Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.
Journal: Leukemia & lymphoma
Published: July 29, 2026
First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level.
Journal: Haematologica
Published: October 10, 2025
First-line tagraxofusp induces durable responses with prolonged survival in adults younger than 50 years with blastic plasmacytoid dendritic cell neoplasm: Post hoc analysis of a phase 2 trial.
Journal: British journal of haematology
Published: August 09, 2025
Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents.
Journal: Blood cancer discovery
Published: June 03, 2025
Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia.
Journal: American journal of hematology
Published: March 21, 2025
Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trial.
Journal: Leukemia & lymphoma
Published: March 11, 2025
Last Updated: 09/26/2026